title: The spectrum of psychiatric symptoms in Wilson's disease: treatment and prognostic considerations.
authors.affiliation: From the Departments of Psychiatry and Internal Medicine, Yale University School of Medicine, and the Wilson Disease Center for Excellence, Yale University Medical Center, New Haven, Conn.
authors.forename: Paula C
authors.initials: PC
authors.lastname: Zimbrean
authors.affiliation: From the Departments of Psychiatry and Internal Medicine, Yale University School of Medicine, and the Wilson Disease Center for Excellence, Yale University Medical Center, New Haven, Conn.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Schilsky
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002194:Capgras Syndrome / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*; D002614:Chelating Agents / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*; D018450:Disease Progression; D005260:Female; D006527:Hepatolenticular Degeneration / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D006801:Humans; D011379:Prognosis; D011618:Psychotic Disorders / Q000188:drug therapy / Q000209:etiology / Q000523:psychology*; D014131:Trace Elements / Q000627:therapeutic use; D014266:Trientine / Q000627:therapeutic use; D015032:Zinc / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002614:Chelating Agents; D014131:Trace Elements; D015032:Zinc; D014266:Trientine